MétaCan
Menu
Back to cohort
Record W7132944348

Effect of Semaglutide on Vascular Regenerative Cells in People at Elevated Risk for Atherosclerosis

2025· dissertation· W7132944348 on OpenAlexfundno aff
Brady Park

Bibliographic record

VenueTSpace · 2025
Typedissertation
Language
FieldBiochemistry, Genetics and Molecular Biology
TopicAngiogenesis and VEGF in Cancer
Canadian institutionsnot available
FundersCanadian Institutes of Health ResearchBanting and Best Diabetes Centre, University of TorontoNovo NordiskUniversity of Toronto
KeywordsSemaglutideType 2 diabetesDiabetes mellitusMaceInflammationCell therapyAgonistAbatacept
DOInot available

Abstract

fetched live from OpenAlex

Background: Cardiovascular outcome trials demonstrated that glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment can reduce major adverse cardiovascular events (MACE) in people with type 2 diabetes (T2D) and/or obesity. However, the mechanisms of vascular benefit remain unknown. In particular, the mechanisms of semaglutide, a potently cardio-protective GLP-1RA that can reduce MACE by up to 26%, requires further elucidation from an immune and vascular standpoint. While the effect of semaglutide on reducing key biomarkers of inflammation are well-established, impact on broader immunomodulatory processes such as hematopoieisis remains elusive. The objective of this thesis was to understand the relationship between GLP-1RA therapy and circulating vascular regenerative (VR) progenitor cells with potent pro-angiogenic,vasculogenic and arteriogenic activity. Aims and Methods: We aimed to determine: 1) the correlation between GLP-1RA use and VR cell content in people with T2D through a retrospective analysis of 92 individuals with T2D sub-classified based on ongoing medication use; 2) whether semaglutide administration could increase VR cell content over 6 months through SEMA-VR CardioLink-15, an open-label, randomized controlled trial that compared the effects of usual care (n=24) versus subcutaneous semaglutide (n=22) in adults with T2D and/or obesity; and 3) the effect of semaglutide across a network of immunomodulatory pathways, using an exploratory serum proteomic analysis of 89 circulating proteins measured through Olink®. Results: In individuals with T2D, background use of GLP-1RA (n=22) was associated with greater VR cell content compared to SGLT2i use (n=42) or use of neither therapy (n=30). SEMA-VR CardioLink-15 confirmed this association, demonstrating that 6-month semaglutide led to increased number of circulating VR cells (hematopoietic myeloid and endothelial precursor cells), while reducing pro-inflammatory granulocyte precursors expressing the neutrophil activation marker CD66b and chemokine receptor CXCR2. Olink® serum proteomic analyses revealed semaglutide induced differential expression of 16 proteins involved in cytokine signaling and immune surveillance, corresponding with a downregulation of biological processes involved in pro-inflammatory TNF and interleukin-signaling via NF-kB, while also regulating hematopoietic differentiation pathways. Conclusion: This thesis provides novel insight into the mechanisms of cardiovascular protection mediated by semaglutide through the enhancement of vessel-regenerative progenitor cell content and regulation of inflammatory networks.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.008
GPT teacher head0.300
Teacher spread0.292 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueTSpaceSame topicAngiogenesis and VEGF in CancerFrench-language works237,207